Hyperion Therapeutics, Inc. (HPTX)

[mlkrborn]

Hyperion Therapeutics confirms its RAVICTI (glycerol phenylbutyrate) liquid received FDA approval for treatment of urea cycle disorders (HPTX) 16.13 +0.50 : Co announced that the FDA has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013.

Separately, co announced it has received notification from the U.S. Patent & Trademark Office (USPTO) of the allowance of the claims of patent application number 13/417,137 entitled, METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS, which discloses optimal measurement timing and target levels for blood ammonia in UCD patients. The issued patent would have a term that expires in March 2032. After issuance, Hyperion plans to list this patent in FDA's Approved Drug Products with Therapeutic Equivalence, or Orange Book.